What's in Helsinn Healthcare SA's pipeline?

Helsinn Healthcare SA has 10 drugs in our index: 2 marketed, 0 filed, 5 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Helsinn Healthcare SA's portfolio?

Top competitors by shared drug class: CCTU, Chongqing University Cancer Hospital, Eye & ENT Hospital of Fudan University, GlaxoSmithKline, Hamad Medical Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/helsinn-healthcare-sa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Helsinn Healthcare SA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Helsinn Healthcare SA pipeline: 2 marketed, 0 filed, 5 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 5 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Akynzeo solution	Akynzeo solution	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)	Oncology
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor	Oncology
Oral palonosetron	Oral palonosetron	phase 3	5-HT3 receptor antagonist	5-HT3 receptor	Oncology
Pro-netupitant/Palonosetron	Pro-netupitant/Palonosetron	phase 3	NK1 receptor antagonist and 5-HT3 receptor antagonist	NK1 receptor and 5-HT3 receptor	Oncology
Placebo to Palonosetron	Placebo to Palonosetron	phase 3	5-HT3 receptor antagonist	5-HT3 receptor	Oncology
Placebo to Ondansetron	Placebo to Ondansetron	phase 3	5-HT3 receptor antagonist	5-HT3 receptor	Oncology, Gastroenterology, Anesthesia
I.V. palonosetron	I.V. palonosetron	phase 3	5-HT3 receptor antagonist	5-HT3 receptor	Oncology

Therapeutic area mix

Oncology · 7
Oncology, Gastroenterology, Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CCTU · 1 shared drug class
Chongqing University Cancer Hospital · 1 shared drug class
Eye & ENT Hospital of Fudan University · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Hamad Medical Corporation · 1 shared drug class
Instituto Mexicano del Seguro Social · 1 shared drug class
LG Life Sciences · 1 shared drug class
Merck & Co. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Helsinn Healthcare SA:

Cite this brief

Drug Landscape (2026). Helsinn Healthcare SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/helsinn-healthcare-sa. Accessed 2026-05-18.